Analyst Ami Fadia of Needham maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $202.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given his Buy rating due to a combination of factors that suggest potential growth and value for Jazz Pharmaceuticals. Despite a slight reduction in the company’s full-year sales guidance, the focus remains on the promising Phase 3 data for Zani’s GEA, expected by the end of the fourth quarter. This, along with upcoming PDUFA dates for Dordaviprone and Zepzelca, are anticipated to drive significant growth for the company in the future.
Additionally, Jazz Pharmaceuticals is well-positioned to enhance shareholder value in the medium term by leveraging its expertise in rare and orphan diseases. The company’s strong financial position supports further business development opportunities. Furthermore, there is an expectation for increased clarity on the company’s strategic direction under the new CEO in the upcoming quarters, which adds to the positive outlook.
In another report released today, Truist Financial also maintained a Buy rating on the stock with a $200.00 price target.